Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 in Relapsed or Refractory Multiple Myeloma
NCT02099539Phase 1Terminated
- Sponsor
- Altor BioScience Corporation
- Start
- Oct 2014
- Primary completion
- Jun 2018
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of nogapendekin alfa inbakicept in multiple myeloma (MM) (6 cohorts), sponsored by Altor BioScience Corporation. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events at 24 weeks and Disease Response Rate of Treated Patients. Started Oct 2014; status: terminated.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02099539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099539.